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Purpose: To evaluate the efficacy of primary chemotherapy combined with local therapy in the treatment of retino-
blastomas not treatable with a single therapeutic method.
Methods: We performed a retrospective chart review of 227 patients diagnosed with retinoblastoma. Sixty-five eyes 
in 52 patients had tumors not treatable with a single therapeutic method and received primary chemotherapy 
combined with local therapy as needed.
Results: Tumor control and eye salvage was achieved in 34 of the 65 eyes; the probability of ocular survival was 
46.56% using the Kaplan-Meier method. Forty-three of the 65 eyes were group D or E tumors, in which tumor 
control and eye salvage was achieved in 16 eyes. Twenty eyes were treated with chemotherapy only, while 28 
eyes received one additional modality of local therapy, and 17 eyes received two modalities of local therapy. Of 
the eyes treated with chemotherapy only, tumor control was achieved in 5 eyes.
Conclusions: Primary chemotherapy combined with local therapy can be effective and safe in the treatment of reti-
noblastomas otherwise untreatable with other therapeutic methods, such as group D and E retinoblastomas. 
More vigorous treatment with more local therapeutic methods combined may yield even better results. 
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Retinoblastoma is a childhood tumor that has a fairly good 
prognosis. Being the most common intraocular malignant tu-
mor in childhood, the overall survival rate approaches 95%, 
with enucleation and external beam radiation therapy 
(EBRT) being the most effective methods for eradicating the 
tumor [1]. Therefore, patients and doctors have recently be-
gun considering salvage of the eye and vision in addition to 
just the survival of the patient. 
Previously, the standard method of treatment for unilateral 
retinoblastoma was enucleation. For bilateral retinoblastomas, 
enucleation of the eye with the more advanced tumor 
and EBRT of the other eye was the standard therapy [2]. 
Enucleation has the disadvantages of total loss of both 
the eye and vision; EBRT is also not without problems 
given the occurrence of secondary malignancies [3] and 
disfigurement of the treated orbit [3-5]. As salvage of the 
eye and vision has become an increasingly important is-
sue in addition to patient survival, there has been an in-
creasing interest in eye-preserving therapeutic methods 
such as primary chemotherapy, laser photocoagulation, 
cryotherapy, thermotherapy, and brachytherapy. These meth-
ods have previously yielded poor outcomes when used as 
a sole therapy. Local therapeutic methods have not been 
able to control the tumor completely and their usage is 
limited to small tumors in certain locations. Chemotherapy 
used alone as a primary method of treatment has also re-
vealed disappointing results in the past. In our previous 
study with prolonged primary chemotherapy for at least 
13 cycles, tumors regressed in size initially but then re-
mained stable [6]. This made it difficult to obtain total Korean J Ophthalmol Vol.24, No.4, 2010
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Table 1. Chemotherapy regimens used in this study
Chemotherapy regimen   Day 0             Day 1  Day 2 Day 3 Day 4 Day 5
Regimen 1 
     Cisplatin 90 mg/m
2/day
     Etoposide 150 mg/m
2/day 150 mg/m
2/day
     Vincristine 1.5 mg/m
2/day
Regimen 2
     Cisplatin 60 mg/m
2/day
     Adriamycin 30 mg/m
2/day
     Etoposide 100 mg/m
2/day 100 mg/m
2/day
     Cyclophosphamide 2 mg/m
2/day 30 mg/kg/day 30 mg/kg/day
        ±vincristine
Regimen 3
     Ifosamide 1.8 g/m
2/day 1.8 g/m
2/day 1.8 g/m
2/day
     Etoposide 150 mg/m
2/day 150 mg/m
2/day 150 mg/m
2/day
     Vincristine 2 mg/m
2/day
regression of large tumors. Prolonged primary chemotherapy 
could be considered as an alternative treatment in tumors 
classified as Reese-Ellsworth classification (R-E classi-
fication) III [7] or less, but should not be considered as a 
useful treatment in high-stage retinoblastoma. Recently, che-
motherapy has been noted to be useful as an adjuvant 
method to reduce tumors too large to treat with local 
therapeutic methods to a more manageable size [2,8-15]. 
Although this has increased the range of tumors that can 
be managed with local therapeutic methods, more advanced 
tumors still have no alternative definitive treatment other 
than enucleation or EBRT. The treatment of such tumors 
remains challenging and many combinations of various 
methods are being investigated.
In this study, we combined local therapeutic methods 
such as thermotherapy, cryotherapy, and laser photocoagulation 
with our previously studied prolonged primary chemotherapy 
regimen for the treatment of retinoblastomas that were 
not treatable with a single therapeutic method.
Materials and Methods
The medical records of 227 patients diagnosed with 
retinoblastoma at Seoul National University Children’s Hospital 
between March 1997 and September 2007 were retro-
spectively studied. The diagnosis of retinoblastoma was 
based on indirect ophthalmoscopy, computed tomography, 
and ultrasonography findings. The stage was assessed 
with R-E classification and the International Classification 
of Retinoblastoma (ICR) [16,17]. Upon diagnosis of reti-
noblastoma, a brain magnetic resonance imaging and bone 
scan were performed to evaluate systemic metastasis. 
Of the patients diagnosed with retinoblastoma, patients 
who had been treated with primary chemotherapy with or 
without the combination of various local therapeutic methods 
were selected and included in this study. Patients whose 
tumors were small and able to be treated with local 
therapeutic methods alone were not included. Patients 
with documented evidence of systemic metastasis or with 
evidence of extraocular extension at diagnosis were also 
excluded. Patients who had chosen to undergo primary 
enucleation after thorough discussion of the available 
treatment options and their prognoses were also not 
included in this study.
Chemotherapy
The chemotherapeutic regimen consisted of a 13-cycle 
combination of cisplatin (carboplatin in some patients), 
etoposide, and vincristine, which is used in the treatment of 
central nervous system tumors [8,18-20]. An ophthalmo-
scopic examination was done either on an outpatient basis 
or under general anesthesia at the beginning of each cycle 
according to the patient’s condition. Additionally, every 
patient was evaluated by a pediatric oncologist regularly 
for possible adverse effects. The chemotherapy regimen 
was changed to regimen 2 if the tumor showed a minimal 
response to the basic regimen or if adverse effects, such 
as nephrotoxicity, were detected. The chemotherapy regi-
men was changed to regimen 3 if the treatment response 
continued to be minimal and if growth of the tumor or 
new lesions were detected despite treatment either with 
the basic regimen or regimen 2. The regimen was also 
modified according to the patients’ general condition and 
if any adverse effect of a specific chemotherapeutic agent 
was suspected. Chemotherapy regimens and dosages used 
in this study are noted in Table 1.
Local therapy
Local therapy such as thermotherapy, cryotherapy, and 
laser photocoagulation was added depending on the status 
of each tumor after each cycle of chemotherapy. Selection 
of the local treatment method was based on tumor size JY Shin, et al. Prolonged Primary Chemotherapy in Retinoblastoma
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Table 2. Patient demographics 
No. of eyes involved
   Bilateral
   Unilateral
Gender
   Male
   Female
Mean age at diagnosis
Mean follow-up period
Mean number of cycles of 
   chemotherapy
42 eyes
*, 29 patients
23 eyes, 23 patients 
34 eyes, 27 patients
31 eyes, 25 patients
13.9 mon (1-40 mon)
53.33 mon (7-115 mon) 
13.37 cycles (1-29 cycles)
* Sixteen eyes in patients with bilateral tumors underwent primary 
enucleation.
Table 3. Treatment outcome of patients according to the Reese-Ellsworth classification (R-E classification) and International 
Classification of Retinoblastoma (ICR)
R-E classification Success rate (%) ICR Success rate (%)
I    7/7 (100) A    8/8 (100)
II 13/15 (86.7) B 10/14 (71.4)
III   6/18 (33.3) C   0/0
IV   6/15 (40) D 15/42 (35.7)
V   2/10 (20) E    1/1 (100)
Total 34/65 (52.3) Total 34/65 (52.3)
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Fig. 1. Probability of ocular survival using the Kaplan-Meier method.
and location [21]. Thermotherapy was done in patients 
with tumors with a base less than 3 mm and a thickness 
less than 3 mm without vitreous seeds located posterior 
to the equator. Laser photocoagulation was done in similar 
cases, but also in slightly larger tumors by surrounding 
the tumor and closing off feeding vessels. Cryotherapy 
was done in lesions similar in size but located anterior to 
the equator. Brachytherapy was not available and was not 
used in this study. 
The patients were grouped according to tumor classification 
(R-E classification, ICR), therapeutic methods used, and the 
status of the contralateral eye. Treatment outcome was assessed 
as whether or not enucleation was required. Enucleation 
was performed in eyes with tumors that showed persistent 
viable appearance with no signs of regression or in eyes 
with newly appearing lesions after two or more cycles of 
treatment. Enucleation was also performed in eyes with 
media opacities rendering their tumors impossible to 
follow. The patients in which tumors had totally regressed 
and therefore avoided enucleation were considered to 
have had a favorable outcome. EBRT was not performed 
as a salvage treatment due to the superior efficacy of enu-
cleation in tumor control and the possible occurrence of 
secondary malignancy and disfigurement of the orbit. 
Informed consent was obtained from every patient at 
the time of diagnosis and initiation of treatment and also 
before the beginning of each cycle of chemotherapy.
Results
Of the 227 patients diagnosed with retinoblastoma in our 
institution, a total of 52 patients, 65 eyes were included 
in this study. The demographics of the included patients 
are summarized in Table 2. The mean age at diagnosis of 
retinoblastoma was 13.9 months. All patients presented 
with leukocoria or strabismus. The mean period of 
follow-up after diagnosis was 53.33 months. The mean 
number of chemotherapy cycles completed was 13.37 cy-
cles per patient.
Overall, 34 eyes achieved total regression of the tumor 
and were able to avoid enucleation. The probability of 
ocular survival was 46.56±6.70% using the Kaplan-Meier 
method (Fig. 1). Treatment outcomes of patients according 
to the R-E classification and ICR are shown in Table 3.
A relatively similar number of patients were in each 
group of R-E classification, but the majority of the eyes 
included in this study were in group D according to the 
ICR. The majority of eyes with tumors of group C or 
lower were excluded from the study because they were 
eligible for local therapy alone. The eyes with group A 
and B tumors that were included in this study had under-
gone primary chemotherapy because of a group D tumor 
in the contralateral eye.
There was a marked difference in the treatment out-
come among patients classified as R-E group I to II and 
R-E group III to V. In patients with R-E classification I 
and II tumors, complete remission of the tumors was 
observed in 100% and 86.7% of patients, respectively. In 
contrast, only 33.3%, 40%, and 20% of the R-E classi-
fication III, IV, and V group patients avoided enucleation, Korean J Ophthalmol Vol.24, No.4, 2010
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Fig. 2. Probability of overall survival using the Kaplan-Meier 
method.
Table 4. Treatment outcome and the number of local treatment modalities used 
Treatment modality No. of salvaged eyes/ total eyes
 R‐E classification ICR
I II III IV V A B C D E
C T x  o n l y   5 / 2 0 14636 050 1 50
CTx+1 LTx 19/28 5 6 5 10 2 4 7 0 16 1
C T x + 2  L T x 1 0 / 1 7 15722 420 1 10
R-E classification=Reese-Ellsworth classification; ICR=International Classification of Retinoblastoma; CTx=chemotherapy; LTx=local 
therapy. 
Table 5. Treatment outcome of patients with unilateral and bilateral tumors
No. of salvaged eyes/total eyes
R-E classification ICR
I II III IV V A B C D E
Unilateral  3/23 0 2 13 3 5 0 3 0 20 0
Bilateral, enucleated 13/16 3 7 2 4 0 4 5 0 6 1
Bilateral, not enucleated 18/26 4 6 3 8 5 3 6 0 16 1
R-E classification=Reese-Ellsworth classification; ICR=International Classification of Retinoblastoma.
respectively. In ICR group D tumor eyes, 35.7% achieved 
successful regression of the tumor.
The local modalities of treatment used in this study 
included cryotherapy, thermotherapy, and laser photo-
coagulation. Twenty eyes in 18 patients received chemo-
therapy only, while 28 eyes in 21 patients were treated 
with chemotherapy and one modality of local therapy. 
Seventeen eyes in 13 patients were treated with chemo-
therapy and two modalities of local therapy. No patients 
were treated with chemotherapy and all three modalities 
of local therapy. Treatment outcomes and the number of 
local modalities used is shown in Table 4. Five of the 20 eyes 
treated with chemotherapy only achieved tumor control.
The treatment outcome of patients with unilateral and 
bilateral involvement is shown in Table 5. Twenty-three 
patients had unilateral involvement. Sixteen patients had 
bilateral involvement with extensive involvement in one 
eye requiring primary enucleation. Thirteen other patients 
had bilateral involvement but did not have to undergo 
primary enucleation. Three out of 23 eyes with unilateral 
involvement were saved while 13 out of the 16 eyes of 
patients with bilateral involvement who had undergone 
primary enucleation of one eye were saved. Eighteen of 
the 26 eyes in patients with bilateral involvement and no 
enucleation were saved. Tumors in the eyes with bilateral 
involvement and enucleation of the more severe eye had 
a significantly lower R-E classification (p=0.001).
Complications of the therapy included mild and man-
ageable complications such as myelosupression, neutropenic 
fever, alopecia, mild nephrotoxicity, and ileus. Only one 
case was fatal, which was due to Fanconi syndrome. The 
probability of overall survival was 96.77±3.17% using the 
Kaplan-Meier method (Fig. 2).
There was one case of hyphema and vitreous hemor-
rhage and one case of cataract, which was thought to be 
due to local therapy, but the direct relationship remains 
uncertain. In both cases enucleation was performed due 
to the limited ability for assessment of tumor progression. 
Discussion
Primary chemotherapy, when combined with local ther-
apy, showed a probability of ocular survival of 46.56% in 
retinoblastomas not treatable with local therapy alone. 
Forty-three cases (66.2%) in this study were group D or 
E tumors, and 16 of these 43 eyes (37.2%) avoided 
enucleation. 
Eye-preserving treatment varies widely throughout the 
world. There have been many studies evaluating the re-
sults of these various treatment methods. Systemic che-
moreduction followed by local therapy has shown various 
tumor control rates up to 78 to 85% [12,14,15]. However, 
when comparing the treatment outcomes of these studies, 
the severity of the tumors in the subjects included in the 
studies should be taken into consideration. These studies 
usually have a heterogeneous severity of tumors included, 
often including a fair proportion of tumors of low severity. 
Our study included only tumors that were considered JY Shin, et al. Prolonged Primary Chemotherapy in Retinoblastoma
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otherwise untreatable with conventional treatment methods, 
which renders direct comparison of these previous survival 
rates with our results irrational. 
Recently, successful tumor control has even been 
reported with chemotherapy alone in more advanced 
tumors. Cohen et al. [22] reported results of chemotherapy 
(with six cycles of vincristine, etoposide, and carboblatin) 
in group D heritable retinoblastoma. Successful tumor 
control with chemotherapy was obtained in only 2 eyes 
(11%), although 9 more eyes (50%) underwent successful 
salvage treatment with EBRT. Shields et al. [23] reported 
results of chemoreduction with 6 cycles of vincristine, 
etoposide, and carboplatin with or without prophylactic 
low-dose EBRT for group E retinoblastoma, with a globe 
salvage rate of 20/42 (48%) in the chemoreduction only 
group and 4/5 (80%) in the chemoreduction and prophy-
lactic low-dose EBRT group. Our results of a globe 
salvage rate of 37.2% in group D or E tumors without 
salvage treatment with EBRT is comparable to the results of 
previous studies. This treatment method can be considered 
an effective method with minimal complications; it is 
especially valuable in bilateral cases when preservation of 
the eye and vision is more critical, or in cases when a 
patient strongly refuses enucleation. 
There was a tendency towards a better outcome in patients 
who were treated with more local treatment modalities. 
The salvage rate was 3/23 (13.0%) in unilateral cases, 
compared to a salvage rate of 18/26 (69.3%) in bilateral 
cases, indicating that there was a tendency towards enu-
cleation in unilateral cases. This may have been due to 
a predilection to completely eradicate the tumor when 
even the slightest amount of evidence of progression was 
present. These findings suggest that with more vigorous 
treatment of the tumor with all possible additional local 
therapeutic methods, the overall eyeball salvage rate 
could be even higher. 
There are many shortcomings of this study due to the 
low prevalence of retinoblastoma. The sample size was small 
and this study was a nonrandomized, retrospective study. 
Also, the local treatment modalities were selected accord-
ing to the individual patient’s conditions and were not 
standardized. The selected secondary chemotherapy regi-
mens were also not standardized. However, many of 
these shortcomings also apply to other studies regarding 
the treatment of retinoblastoma.
In conclusion, chemoreduction and local therapy can be 
considered as a first-line treatment in low grade tumors. 
In higher grade tumors, although enucleation is still the 
treatment of choice in the most severe cases with vitreous 
seeding or massive tumors involving over half the retina, 
chemotherapy combined with local therapy can also be 
given as a choice of treatment to parents in intermediate 
cases, especially in bilateral cases with one eye already 
requiring enucleation. Further study is necessary to de-
termine the most effective chemotherapy regimen and lo-
cal therapy protocol. The tendency of a better outcome in 
patients treated with more modalities of local therapy re-
quires further study.
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